CN106748666A - 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 - Google Patents
一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 Download PDFInfo
- Publication number
- CN106748666A CN106748666A CN201611092814.8A CN201611092814A CN106748666A CN 106748666 A CN106748666 A CN 106748666A CN 201611092814 A CN201611092814 A CN 201611092814A CN 106748666 A CN106748666 A CN 106748666A
- Authority
- CN
- China
- Prior art keywords
- bibenzyl
- extract
- aglaia odorata
- aglaia
- odorata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 15
- 208000008589 Obesity Diseases 0.000 title claims abstract description 10
- 235000020824 obesity Nutrition 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 14
- 230000002218 hypoglycaemic effect Effects 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title abstract description 8
- 240000000595 Aglaia odorata Species 0.000 claims abstract description 35
- 235000010887 Aglaia odorata Nutrition 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 241000730318 Aglaia abbreviata Species 0.000 claims abstract description 7
- 235000013402 health food Nutrition 0.000 claims abstract description 5
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000003208 petroleum Substances 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000002024 ethyl acetate extract Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000001641 gel filtration chromatography Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 206010018473 Glycosuria Diseases 0.000 claims 1
- 241000158728 Meliaceae Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 239000013641 positive control Substances 0.000 abstract description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 abstract description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 abstract description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 abstract description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 229940100243 oleanolic acid Drugs 0.000 abstract description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 abstract description 3
- 108090000371 Esterases Proteins 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 6
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FYKHWKNFKLTGNX-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1.OC1=CC=C([N+]([O-])=O)C=C1 FYKHWKNFKLTGNX-UHFFFAOYSA-N 0.000 description 1
- KBOQXVVZFSWICE-FIJLXMTKSA-N 5-[(8R,9S,10R,13R,14S,17R)-14-hydroxy-10,13-dimethyl-1,2,7,8,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CCC=CC5=CC4)C)CC[C@@]32C)C=CC(=O)OC=1 KBOQXVVZFSWICE-FIJLXMTKSA-N 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- -1 tyrosine ester Chemical class 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
- C07C37/685—Processes comprising at least two steps in series
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611092814.8A CN106748666B (zh) | 2016-12-01 | 2016-12-01 | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611092814.8A CN106748666B (zh) | 2016-12-01 | 2016-12-01 | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106748666A true CN106748666A (zh) | 2017-05-31 |
CN106748666B CN106748666B (zh) | 2021-01-05 |
Family
ID=58913762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611092814.8A Expired - Fee Related CN106748666B (zh) | 2016-12-01 | 2016-12-01 | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106748666B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153883A (zh) * | 2020-01-17 | 2020-05-15 | 中国热带农业科学院热带生物技术研究所 | 一种混元萜类化合物Verruculide B4及其制备方法和应用 |
CN111302942A (zh) * | 2020-04-09 | 2020-06-19 | 中国热带农业科学院热带生物技术研究所 | 具有ptp1b抑制活性的化合物及其应用 |
CN113388563A (zh) * | 2021-06-01 | 2021-09-14 | 南昌大学 | 一种具有降糖作用的大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
CN113416683A (zh) * | 2021-06-01 | 2021-09-21 | 南昌大学 | 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
CN113461532A (zh) * | 2021-07-05 | 2021-10-01 | 南昌大学 | 一种具有降血糖作用的黑桑素a及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014252A2 (en) * | 2000-08-16 | 2002-02-21 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
-
2016
- 2016-12-01 CN CN201611092814.8A patent/CN106748666B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014252A2 (en) * | 2000-08-16 | 2002-02-21 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
Non-Patent Citations (1)
Title |
---|
TOSHINORI ASAKAWA等: "PRENYL BIBENZYLS FROM THE LIVER WORT RADULA KOJANA", 《PHYTOCHEMISTRY》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153883A (zh) * | 2020-01-17 | 2020-05-15 | 中国热带农业科学院热带生物技术研究所 | 一种混元萜类化合物Verruculide B4及其制备方法和应用 |
CN111153883B (zh) * | 2020-01-17 | 2022-04-08 | 中国热带农业科学院热带生物技术研究所 | 一种混元萜类化合物Verruculide B4及其制备方法和应用 |
CN111302942A (zh) * | 2020-04-09 | 2020-06-19 | 中国热带农业科学院热带生物技术研究所 | 具有ptp1b抑制活性的化合物及其应用 |
CN111302942B (zh) * | 2020-04-09 | 2022-03-01 | 中国热带农业科学院热带生物技术研究所 | 具有ptp1b抑制活性的化合物及其应用 |
CN113388563A (zh) * | 2021-06-01 | 2021-09-14 | 南昌大学 | 一种具有降糖作用的大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
CN113416683A (zh) * | 2021-06-01 | 2021-09-21 | 南昌大学 | 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
CN113461532A (zh) * | 2021-07-05 | 2021-10-01 | 南昌大学 | 一种具有降血糖作用的黑桑素a及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106748666B (zh) | 2021-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106748666A (zh) | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 | |
Bu et al. | α‐glucosidase inhibition and the in vivo hypoglycemic effect of butyl‐isobutyl‐phthalate derived from the Laminaria japonica rhizoid | |
Fernandez et al. | Isoquercitrin from Argemone platyceras inhibits carbachol and leukotriene D4-induced contraction in guinea-pig airways | |
Selvaraj et al. | Effect of Glycosin alkaloid from Rhizophora apiculata in non-insulin dependent diabetic rats and its mechanism of action: In vivo and in silico studies | |
Thabet et al. | Validation of the antihyperglycaemic and hepatoprotective activity of the flavonoid rich fraction of Brachychiton rupestris using in vivo experimental models and molecular modelling | |
CN106916133B (zh) | 一种具有抑制ptp1b活性的间苯三酚衍生物及其制备方法、应用 | |
CN104163844B (zh) | 甾体烯酮类化合物蕨藻烯酮及其制备和用途 | |
CN107802626A (zh) | 降血糖组合物及其制备方法、用途 | |
CN107805269A (zh) | Dictyopterisinf及其制备糖尿病或肥胖症药物中的应用 | |
Wang et al. | Studies on the key constituents and the related mechanisms of Clerodendranthus spicatus in the treatment of diabetes based on network pharmacology | |
Cristians et al. | Hypoglycemic activity of extracts and compounds from the leaves of Hintonia standleyana and H. latiflora: potential alternatives to the use of the stem bark of these species | |
CN107674108A (zh) | 豆甾烷型甾体类化合物在制备糖尿病或肥胖症药物中的应用 | |
CN104224813B (zh) | 一种药物组合物及其制备方法与用途 | |
CN105949104B (zh) | 一种血红素酸酯化的链状二萜类化合物的用途 | |
CN106749147B (zh) | 降血糖化合物及其制备方法、用途 | |
CN106748664A (zh) | 具有降血糖作用的新联苄类天然药物及其用途 | |
CN101474314A (zh) | 儿茶素在制药中的应用 | |
CN106748778A (zh) | 具有降血糖作用的一种新联苄类天然药物及其制备方法和用途 | |
CN107652347A (zh) | 化合物DictyopterisinI及其在制备糖尿病或肥胖症药物中的用途 | |
CN100478015C (zh) | 一种治疗过敏性鼻炎的中药组合物及其制备方法 | |
CN105384717B (zh) | 甘松新酮类化合物及其制备方法与应用 | |
Sulastri et al. | Antidiabetic formulation development based on natural materials as α-glucosidase enzyme inhibitor | |
CN106580933B (zh) | 3,5-二羟基-2-[3,7-二甲基-2(反式),6-辛二烯基]-联苄的用途 | |
CN107722098A (zh) | 化合物dictyopterisinc及其在制备糖尿病或肥胖症药物中的应用 | |
CN105646151A (zh) | 一种炔类化合物及其制备方法和该化合物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211201 Address after: Zone E, 23rd floor, block D, building 1, No. 6, Jianguomenwai street, Chaoyang District, Beijing 100020 Patentee after: Yilian housekeeper health management (Beijing) Co.,Ltd. Address before: 999 No. 330031 Jiangxi province Nanchang Honggutan University Avenue Patentee before: Nanchang University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230403 Address after: 12A02, 11th Floor, No. C2 East Third Ring North Road, Chaoyang District, Beijing, 100020 Patentee after: Beijing Traditional Chinese Medicine Alliance Health Technology Co.,Ltd. Address before: Zone E, 23rd floor, block D, building 1, No. 6, Jianguomenwai street, Chaoyang District, Beijing 100020 Patentee before: Yilian housekeeper health management (Beijing) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210105 |
|
CF01 | Termination of patent right due to non-payment of annual fee |